Search - tctmd.com

Displaying 1 - 20 of 91

Sort: Relevancy | Date

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

Shelley Wood

September 30, 2020

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Daily News

先前的动脉粥样硬化会升高急性心肌梗死后的死亡风险

Michael O'Riordan

December 09, 2016

News Daily News

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

Michael O'Riordan

December 09, 2016

News Daily News

Los Antecedentes de Aterosclerosis Aumentan el Riesgo de Morir Post-IAM

Michael O'Riordan

December 09, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

Tratamiento Antiplaquetario en Pacientes con Stents que Necesitan Cirugía: La Experiencia de Italia Marca el Camino a Seguir

Michael O'Riordan

July 20, 2016

Advertisement

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

LDL Control Remains Poor in CAD Patients: NHANES

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

ESC Updates Guidelines for Treating STEMI Patients

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

先前的动脉粥样硬化会升高急性心肌梗死后的死亡风险

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

Los Antecedentes de Aterosclerosis Aumentan el Riesgo de Morir Post-IAM

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Tratamiento Antiplaquetario en Pacientes con Stents que Necesitan Cirugía: La Experiencia de Italia Marca el Camino a Seguir

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content